The use of topical propranolol in pyogenic granulomas - CDP0902

• Conditions: pyogenic granulomas; MedDRA version: 9.1Level: LLTClassification code 10029539

• Registration Number: EUCTR2009-014572-22-IT
• Lead Sponsor: AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-07-19
• Last Update Posted: 24 February 2014

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Patients > 4 weeks of age and Adult patients with pyogenic granuloma Pediatric Patients whose parents have signed a informed consent or adult patients who have signed an informed consent
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- Hypersensitivity to propranolol in first degree relatives - Severe clinical conditions that contraindicate the inclusion in the study

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: The aim of this study is to report the efficacy of the topical propranolol 1% in the treatment of pyogenic granulomas;Secondary Objective: the tollerability of the topical propranolol 1% in the treatment of pyogenic granulomas;Primary end point(s): the efficacy of the topical propranolol 1% in the treatment of pyogenic granulomas in the terms of reduction /dissappearing of the cutaneous lesion